The shocking results While comparing the two groups, they found that patients taking a GLP-1 medication had up to a 29% higher risk of developing a chronic cough within the first five years of treatment

: Recombinant Factor VIII, Plasma-Derived Factor VIII, Extended Half-life Factor VIII, Desmopressin Adjuncts : Hemophilia A Treatment, Surgery Support, Genetic Deficiency Therapy, Prophylaxis Therapy : North America, Europe, Asia-Pacific, South America, Middle East & Africa : CSL Vifor, Octapharma, Grifols, BPL Plasma, LFB, Kedrion Biopharma, Bio Products Laboratory Limited, TAKEDA PHARMACEUTICALS AMERICA, INC., Sanofi, KAMADA, Green Cross Health, Octapharma Plasma, Inc., Baxalta, Catalyst Biosciences, Inhibrx Biosciences, Inc., Rigel Pharmaceuticals Inc., Aptevo Therapeutics Inc, Admac Oncology- Dedicated Oncology Facility, Thermo Fisher Scientific, Emergent BioSolutions, argenx, CSL, Fusion Pharmaceuticals, Medexus Pharmaceuticals, Sartorius, ProteinSimple, a Bio-Techne brand, Biotest AG, Viatris, Mallinckrodt Pharmaceuticals, HEMA Biologics, Catalent Pharma Solutions Brasil, Recipharm, Lonza, Zymeworks Inc., Alvotech, Arcturus Therapeutics, BioMarin Pharmaceutical Inc., Fresenius Kabi, West Pharmaceutical Services #humanfactorviii #pharmaceuticalresearch #hemophiliatherapy #recombinantdrugs #plasmaderivedproteins #biosimilarbiotech #blooddisorders #drugdevelopment #clinicalinnovation To view or add a comment, sign in More from this author Explore related topics Explore content categories

Wegovy and Ozempic both contain semaglutide, but Wegovy provides a higher dose
Here is how to handle common problems: What if I leave my pen out in a hot car